Teva Pharmaceutical Industries Limited last reported quarterly results on Nov 3, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $4.4 billion (-1.9% year over year) and diluted EPS of $0.20. It usually reports 12–34 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–34 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 3, 2026
34 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
4,395
-1.9%
|
233
-46.2%
|
0.20
-45.9%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
4,142
-0.8%
|
-576
-304.3%
|
-0.49
-304.2%
|
|
Apr 29, 2026
29 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
3,982
+2.3%
|
369
+72.4%
|
0.31
+72.2%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
4,711
+11.4%
|
480
+321.2%
|
0.41
+314.0%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
4,480
+3.4%
|
433
+199.1%
|
0.37
+194.9%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
4,176
+0.3%
|
282
+133.3%
|
0.24
+132.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3,891
+1.9%
|
214
+254.0%
|
0.18
+250.0%
|
|
Jan 29, 2025
29 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
4,229
-5.1%
|
-217
-146.9%
|
-0.19
-146.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TEVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Large accelerated filer
- SEC CIK
- 818686
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED (until Jan 16, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.